Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
Yonghao Yu,1
Sang-Oh Yoon,1,*
George Poulogiannis,2
Qian Yang,1,3
Xiaoju Max Ma,1,
Judit Villén,1,
Neil Kubica,1,
Gregory R. Hoffman,1
Lewis C. Cantley,2
Steven P. Gygi,1,||
John Blenis1,||
Abstract:
The evolutionarily conserved serine-threonine kinase mammalian target of rapamycin (mTOR) plays a critical role in regulating many pathophysiological processes. Functional characterization of the mTOR signaling pathways, however, has been hampered by the paucity of known substrates. We used large-scale quantitative phosphoproteomics experiments to define the signaling networks downstream of mTORC1 and mTORC2. Characterization of one mTORC1 substrate, the growth factor receptor–bound protein 10 (Grb10), showed that mTORC1-mediated phosphorylation stabilized Grb10, leading to feedback inhibition of the phosphatidylinositol 3-kinase (PI3K) and extracellular signal–regulated, mitogen-activated protein kinase (ERK-MAPK) pathways. Grb10 expression is frequently down-regulated in various cancers, and loss of Grb10 and loss of the well-established tumor suppressor phosphatase PTEN appear to be mutually exclusive events, suggesting that Grb10 might be a tumor suppressor regulated by mTORC1.
1 Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA. 2 Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. 3 Harvard School of Dental Medicine, Boston, MA 02115, USA.
* Present address: Department of Cancer and Cell Biology, University of Cincinnati, College of Medicine, Cincinnati, OH 45267, USA.
Present address: Department of Research Oncology Diagnostics, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Present address: Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
Present address: Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
|| To whom correspondence should be addressed. E-mail: steven_gygi{at}hms.harvard.edu (S.P.G); john_blenis{at}hms.harvard.edu (J.B.)
The editors suggest the following Related Resources on Science sites:
In Science Magazine
PERSPECTIVES
Sung Su Yea and David A. Fruman (10 June 2011) Science332 (6035), 1270.
[DOI: 10.1126/science.1208071] |Summary »|Full Text »|PDF »
REPORTS
Peggy P. Hsu, Seong A. Kang, Jonathan Rameseder, Yi Zhang, Kathleen A. Ottina, Daniel Lim, Timothy R. Peterson, Yongmun Choi, Nathanael S. Gray, Michael B. Yaffe, Jarrod A. Marto, and David M. Sabatini (10 June 2011) Science332 (6035), 1317.
[DOI: 10.1126/science.1199498] |Abstract »|Full Text »|PDF »|Supporting Online Material »
In Science Signaling
EDITORS' CHOICE
L. Bryan Ray (14 June 2011) Sci. Signal.4 (177), ec165.
[DOI: 10.1126/scisignal.4177ec165] |Abstract »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation.
A. J. Streets, O. Wessely, D. J. M. Peters, and A. C. M. Ong (2013)
Hum. Mol. Genet.
22, 1924-1939
|Abstract »|Full Text »|PDF »
Protein Phosphatase 2A and DNA-dependent Protein Kinase Are Involved in Mediating Rapamycin-induced Akt Phosphorylation.
Y. Li, X. Wang, P. Yue, H. Tao, S. S. Ramalingam, T. K. Owonikoko, X. Deng, Y. Wang, H. Fu, F. R. Khuri, et al. (2013)
J. Biol. Chem.
288, 13215-13224
|Abstract »|Full Text »|PDF »
Mammalian Target of Rapamycin Complex 1 (mTORC1)-mediated Phosphorylation Stabilizes ISCU Protein: IMPLICATIONS FOR IRON METABOLISM.
Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells.
W. Fiskus, S. Verstovsek, T. Manshouri, J. E. Smith, K. Peth, S. Abhyankar, J. McGuirk, and K. N. Bhalla (2013)
Mol. Cancer Ther.
12, 577-588
|Abstract »|Full Text »|PDF »
Regulation of mTORC1 and its impact on gene expression at a glance.
M. Laplante and D. M. Sabatini (2013)
J. Cell Sci.
126, 1713-1719
|Full Text »|PDF »
A RANKL-PKC{beta}-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts.
M. Ferron, C. Settembre, J. Shimazu, J. Lacombe, S. Kato, D. J. Rawlings, A. Ballabio, and G. Karsenty (2013)
Genes & Dev.
27, 955-969
|Abstract »|Full Text »|PDF »
Insulin Signaling in Type 2 Diabetes: EXPERIMENTAL AND MODELING ANALYSES REVEAL MECHANISMS OF INSULIN RESISTANCE IN HUMAN ADIPOCYTES.
C. Brannmark, E. Nyman, S. Fagerholm, L. Bergenholm, E.-M. Ekstrand, G. Cedersund, and P. Stralfors (2013)
J. Biol. Chem.
288, 9867-9880
|Abstract »|Full Text »|PDF »
Large FK506-Binding Proteins Shape the Pharmacology of Rapamycin.
A. M. Marz, A.-K. Fabian, C. Kozany, A. Bracher, and F. Hausch (2013)
Mol. Cell. Biol.
33, 1357-1367
|Abstract »|Full Text »|PDF »
Cyr61, a Matricellular Protein, Is Needed for Dendritic Arborization of Hippocampal Neurons.
A. R. Malik, M. Urbanska, A. Gozdz, L. J. Swiech, A. Nagalski, M. Perycz, M. Blazejczyk, and J. Jaworski (2013)
J. Biol. Chem.
288, 8544-8559
|Abstract »|Full Text »|PDF »
Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1.
I. Ben-Sahra, J. J. Howell, J. M. Asara, and B. D. Manning (2013)
Science
339, 1323-1328
|Abstract »|Full Text »|PDF »
Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis.
A. M. Robitaille, S. Christen, M. Shimobayashi, M. Cornu, L. L. Fava, S. Moes, C. Prescianotto-Baschong, U. Sauer, P. Jenoe, and M. N. Hall (2013)
Science
339, 1320-1323
|Abstract »|Full Text »|PDF »
Molecular Dissection of AKT Activation in Lung Cancer Cell Lines.
Host mTORC1 Signaling Regulates Andes Virus Replication.
S. McNulty, M. Flint, S. T. Nichol, and C. F. Spiropoulou (2013)
J. Virol.
87, 912-922
|Abstract »|Full Text »|PDF »
BSTA Promotes mTORC2-Mediated Phosphorylation of Akt1 to Suppress Expression of FoxC2 and Stimulate Adipocyte Differentiation.
Y. Yao, M. Suraokar, B. G. Darnay, B. G. Hollier, T. E. Shaiken, T. Asano, C.-H. Chen, B. H.- J. Chang, Y. Lu, G. B. Mills, et al. (2013)
Science Signaling
6, ra2
|Abstract »|Full Text »|PDF »
Mammalian Target of Rapamycin (mTOR) Signaling Network in Skeletal Myogenesis.
Disruption of Growth Factor Receptor-Binding Protein 10 in the Pancreas Enhances {beta}-Cell Proliferation and Protects Mice From Streptozotocin-Induced {beta}-Cell Apoptosis.
J. Zhang, N. Zhang, M. Liu, X. Li, L. Zhou, W. Huang, Z. Xu, J. Liu, N. Musi, R. A. DeFronzo, et al. (2012)
Diabetes
61, 3189-3198
|Abstract »|Full Text »|PDF »
mTOR-Dependent Cell Survival Mechanisms.
C.-M. Hung, L. Garcia-Haro, C. A. Sparks, and D. A. Guertin (2012)
Cold Spring Harb Perspect Biol
4, a008771
|Abstract »|Full Text »|PDF »
Targeted Proteomics for Determining Phosphorylation Site-Specific Associations in Cardiovascular Disease.
S. J. Cordwell and M. Y. White (2012)
Circulation
126, 1803-1807
|Full Text »|PDF »
Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features.
E. Yuan, P. T. Tsai, E. Greene-Colozzi, M. Sahin, D. J. Kwiatkowski, and I. A. Malinowska (2012)
Hum. Mol. Genet.
21, 4286-4300
|Abstract »|Full Text »|PDF »
Protein abundance is key to distinguish promiscuous from functional phosphorylation based on evolutionary information.
E. D. Levy, S. W. Michnick, and C. R. Landry (2012)
Phil Trans R Soc B
367, 2594-2606
|Abstract »|Full Text »|PDF »
PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma.
A. L. Ho, S. D. Vasudeva, M. Lae, T. Saito, V. Barbashina, C. R. Antonescu, M. Ladanyi, and G. K. Schwartz (2012)
Cancer Res.
72, 4515-4525
|Abstract »|Full Text »|PDF »
Comment on "A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation": Building a Model of the mTOR Signaling Network with a Potentially Faulty Tool.
Response to Comment on "A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation": Building a Model of the mTOR Signaling Network with a Potentially Faulty Tool.
P. Dalle Pezze, A. G. Sonntag, D. P. Shanley, and K. Thedieck (2012)
Science Signaling
5, lc4
|Abstract »|Full Text »|PDF »
MMFPh: a maximal motif finder for phosphoproteomics datasets.
T. Wang, A. N. Kettenbach, S. A. Gerber, and C. Bailey-Kellogg (2012)
Bioinformatics
28, 1562-1570
|Abstract »|Full Text »|PDF »
Role of PRAS40 in Akt and mTOR signaling in health and disease.
C. Wiza, E. B. M. Nascimento, and D. M. Ouwens (2012)
Am J Physiol Endocrinol Metab
302, E1453-E1460
|Abstract »|Full Text »|PDF »
Research Resource: Identification of Novel Growth Hormone-Regulated Phosphorylation Sites by Quantitative Phosphoproteomics.
B. N. Ray, H. K. Kweon, L. S. Argetsinger, D. C. Fingar, P. C. Andrews, and C. Carter-Su (2012)
Mol. Endocrinol.
26, 1056-1073
|Abstract »|Full Text »|PDF »
Inhibition of mTORC1 Kinase Activates Smads 1 and 5 but Not Smad8 in Human Prostate Cancer Cells, Mediating Cytostatic Response to Rapamycin.
R. S. Wahdan-Alaswad, K. L. Bane, K. Song, D. T. N. Shola, J. A. Garcia, and D. Danielpour (2012)
Mol. Cancer Res.
10, 821-833
|Abstract »|Full Text »|PDF »
Leucine and mTORC1: a complex relationship.
K. M. Dodd and A. R. Tee (2012)
Am J Physiol Endocrinol Metab
302, E1329-E1342
|Abstract »|Full Text »|PDF »
Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications.
J. C. Montero, X. Chen, A. Ocana, and A. Pandiella (2012)
Mol. Cancer Ther.
11, 1342-1352
|Abstract »|Full Text »|PDF »
Structure-Activity Analysis of Niclosamide Reveals Potential Role for Cytoplasmic pH in Control of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling.
B. D. Fonseca, G. H. Diering, M. A. Bidinosti, K. Dalal, T. Alain, A. D. Balgi, R. Forestieri, M. Nodwell, C. V. Rajadurai, C. Gunaratnam, et al. (2012)
J. Biol. Chem.
287, 17530-17545
|Abstract »|Full Text »|PDF »
Global Detection of Protein Kinase D-dependent Phosphorylation Events in Nocodazole-treated Human Cells.
M. Franz-Wachtel, S. A. Eisler, K. Krug, S. Wahl, A. Carpy, A. Nordheim, K. Pfizenmaier, A. Hausser, and B. Macek (2012)
Mol. Cell. Proteomics
11, 160-170
|Abstract »|Full Text »|PDF »
Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types.
M. F. James, E. Stivison, R. Beauchamp, S. Han, H. Li, M. R. Wallace, J. F. Gusella, A. O. Stemmer-Rachamimov, and V. Ramesh (2012)
Mol. Cancer Res.
10, 649-659
|Abstract »|Full Text »|PDF »
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy.
C. Garcia-Garcia, Y. H. Ibrahim, V. Serra, M. T. Calvo, M. Guzman, J. Grueso, C. Aura, J. Perez, K. Jessen, Y. Liu, et al. (2012)
Clin. Cancer Res.
18, 2603-2612
|Abstract »|Full Text »|PDF »
Signal transduction pathways in FSH regulation of rat Sertoli cell proliferation.
M. F. Riera, M. Regueira, M. N. Galardo, E. H. Pellizzari, S. B. Meroni, and S. B. Cigorraga (2012)
Am J Physiol Endocrinol Metab
302, E914-E923
|Abstract »|Full Text »|PDF »
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.
A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation.
P. Dalle Pezze, A. G. Sonntag, A. Thien, M. T. Prentzell, M. Godel, S. Fischer, E. Neumann-Haefelin, T. B. Huber, R. Baumeister, D. P. Shanley, et al. (2012)
Science Signaling
5, ra25
|Abstract »|Full Text »|PDF »
Targeting the mTOR/4E-BP Pathway in Endometrial Cancer.
S. B. Korets, S. Czok, S. V. Blank, J. P. Curtin, and R. J. Schneider (2011)
Clin. Cancer Res.
17, 7518-7528
|Abstract »|Full Text »|PDF »
Targeting of Insulin-Like Growth Factor Type 1 Receptor in Ewing Sarcoma: Unfulfilled Promise or a Promising Beginning?.
A. L. Ho and G. K. Schwartz (2011)
J. Clin. Oncol.
29, 4581-4583
|Full Text »|PDF »
Liver-specific Inducible Nitric-oxide Synthase Expression Is Sufficient to Cause Hepatic Insulin Resistance and Mild Hyperglycemia in Mice.
S. Shinozaki, C. S. Choi, N. Shimizu, M. Yamada, M. Kim, T. Zhang, H. H. Dong, Y.-B. Kim, and M. Kaneki (2011)
J. Biol. Chem.
286, 34959-34975
|Abstract »|Full Text »|PDF »
The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile.
B. T. Wang, G. S. Ducker, A. J. Barczak, R. Barbeau, D. J. Erle, and K. M. Shokat (2011)
PNAS
108, 15201-15206
|Abstract »|Full Text »|PDF »
mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinase-Driven Feedback Loop.